ArticleG3 (Bethesda, Md.)2022
Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole.
Article in G3 (Bethesda, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- The evolution of azole resistance through a reduced spore dormancy pathway associated with loss of SUMOylation function inApplied and environmental microbiology · 2026Article
- Experimental Evolution of PathogenicMicroorganisms · 2026Review
- ER stress selects forFrontiers in microbiology · 2026Article
- HyperdCas12a-based multiplexed genetic regulation in Candida albicans.Nucleic acids research · 2025Article
- Migration and standing variation in vaginal and rectal yeast populations in recurrent vulvovaginal candidiasis.mSystems · 2025Article
- Article
- The impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance.FEMS microbiology reviews · 2025Review
- The role of gene copy number variation in antimicrobial resistance in human fungal pathogens.npj antimicrobials and resistance · 2025Review
- Understanding adaptation to fluconazole: comparative insights into tolerance and resistance inFrontiers in cellular and infection microbiology · 2025Article
- Uncovering the connection between tunicamycin-induced respiratory deficiency and reduced fluconazole tolerance inFrontiers in microbiology · 2025Article
- Unlocking the potential of experimental evolution to study drug resistance in pathogenic fungi.npj antimicrobials and resistance · 2024Review
- Single-cell detection of copy number changes reveals dynamic mechanisms of adaptation to antifungals in Candida albicans.Nature microbiology · 2024Article
- Evolution and strain diversity advance exploration ofmSphere · 2024Review
- Erg251 has complex and pleiotropic effects on sterol composition, azole susceptibility, filamentation, and stress response phenotypes.PLoS pathogens · 2024Article
- Beyond resistance: antifungal heteroresistance and antifungal tolerance in fungal pathogens.Current opinion in microbiology · 2024Review
- Article
- Parallel evolution of fluconazole resistance and tolerance inFrontiers in cellular and infection microbiology · 2024Article
- Miconazole induces aneuploidy-mediated tolerance inFrontiers in cellular and infection microbiology · 2024Article
- Ketoconazole induces reversible antifungal drug tolerance mediated by trisomy of chromosome R inFrontiers in microbiology · 2024Article
- Genomic epidemiology of antifungal resistance in human and avian isolates ofFrontiers in veterinary science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of in vitro studies have examined the acquisition of drug resistance to the triazole fluconazole, a first-line treatment for many Candida infections. Much less is known about posaconazole, a newer triazole. We conducted the first in vitro experimental evolution of replicates from 8 diverse strains of Candida albicans in a high level of the fungistatic drug posaconazole. Approximately half of the 132 evolved replicates survived 50 generations of evolution, biased toward some of the strain backgrounds. We found that although increases in drug resistance were rare, increases in drug tolerance (the slow growth of a subpopulation of cells in a level of drug above the resistance level) were common across strains. We also found that adaptation to posaconazole resulted in widespread cross-tolerance to other azole drugs. Widespread aneuploidy was observed in evolved replicates from some strain backgrounds. Trisomy of at least one of chromosomes 3, 6, and R was identified in 11 of 12 whole-genome sequenced evolved SC5314 replicates. These findings document rampant evolved cross-tolerance among triazoles and highlight that increases in drug tolerance can evolve independently of drug resistance in a diversity of C. albicans strain backgrounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.